Latest Ketorolac Stories

SUNNYVALE, Calif., Jan. 3, 2013 /PRNewswire/ -- Icon Bioscience, Inc., (IBI), a privately held biopharmaceutical company that specializes in the development and commercialization of novel ophthalmic pharmaceuticals, today announced that melphalan intraocular injection, the company's investigational product for the treatment of retinoblastoma, has been granted Orphan Drug Designation by the U.S. Food & Drug Administration (FDA). Orphan Drug Designation is generally granted to...

SHIRLEY, N.Y., June 25, 2012 /PRNewswire/ -- Regency Therapeutics, a division of Luitpold Pharmaceuticals, Inc., announced today that a national registry has been launched by a group of academic emergency medicine specialists led by Charles Pollack, MA, MD, FAAEM, FACEP, FAHA, Professor and Chairman, Department of Emergency Medicine, Pennsylvania Hospital, University of Pennsylvania Health System. The purpose of the registry is to evaluate patient experience with SPRIX®...

KINGSTON, ON, June 18, 2012 /PRNewswire/ - At the center of the debate of how to potentially save the healthcare system millions of dollars are two drugs used to treat wet age-related macular degeneration (AMD), the leading cause of blindness in seniors. One, Lucentis, is FDA and Health Canada-approved and costs $1,700.  The other, Avastin, is used off-label and costs one-tenth the price. Eye doctors currently use both drugs to treat AMD and some studies have shown that they are...

DIEPENBEEK, Belgium, May 11, 2012 /PRNewswire/ -- - Appointments deepen ophthalmology, product development and corporate development experience Amakem NV, a kinase platform company focusing on ophthalmology, today announces the appointment of Dr. Steve Pakola as Chief Medical Officer and Dr. George Lasezkay to its Board as an Independent Director. Both have exceptional track records in the biotechnology industry and bring a wealth of ophthalmology experience to Amakem....

SEATTLE, March 29, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today reported the allowance by the US Patent and Trademark Office (USPTO) of an additional patent claiming intraocular surgical methods of using OMS302, the Company's ophthalmological PharmacoSurgery(TM) product. The issued patent will have a term extending through July 2023. Currently in Phase 3 clinical development, OMS302 is designed to maintain intraoperative mydriasis (pupil dilation) and reduce pain in...

Does not have the side effects of fentanyl and other narcotics Patients who have undergone sinus surgery can safely take an alternative pain medication that does not cause the side effects of narcotics such as fentanyl and Vicodin, a Loyola University Health System study has found. The alternative medication is ketorolac (brand name, Toradol). It is in the same class of nonsteroidal anti-inflammatory drugs as Advil and Aleve. Ketorolac does not cause the side effects that narcotic drugs...

GREENWOOD VILLAGE, Colo., Oct. 18, 2011 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ:AMPE) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), today announced that it has demonstrated in an IRB approved, randomized, placebo controlled, double-blinded proof of concept study, that low dose intranasal danazol has an impact on allergic rhinitis, a clinical condition in which increases in vascular...

(Ivanhoe Newswire) "“ For the first time scientists have accomplished a laboratory synthesis of a rare natural product isolated from the bark of a plant widely employed in traditional medicine. This advance may provide the scientific foundation to develop an effective alternative to commonly prescribed narcotic pain treatments.The study defines a chemical means to access meaningful quantities of the rare natural product conolidine. Based on data from mouse models, the study also suggests...

SHIRLEY, N.Y. and PARSIPPANY, N.J., May 17, 2011 /PRNewswire/ -- Regency Therapeutics, a newly established division of Luitpold Pharmaceuticals, Inc., and its co-promotion partner Daiichi Sankyo, Inc., announced today that they have launched SPRIX® (ketorolac tromethamine) Nasal Spray and that it is now commercially available. SPRIX® was approved by the U.S. Food and Drug Administration (FDA) in May 2010 for the short-term (up to 5 days) management of moderate to moderately severe...

SHIRLEY, N.Y., April 21, 2011 /PRNewswire/ -- Luitpold Pharmaceuticals, Inc. ("Luitpold") today announced that it has temporarily suspended distribution of all of its drug products manufactured at its Shirley, New York facility and marketed by its American Regent, Inc. subsidiary and Animal Health Division. This action DOES NOT affect products manufactured at its PharmaForce Inc. subsidiary, including its Betamethasone Sodium Phosphate and Betamethasone Sodium Acetate Injectable...